Inactive Instrument

Verseon Corp

Equities

USU9221J1098

Biotechnology & Medical Research

Verseon Corporation Appoints Robert W. Karr as Non-Executive Class II Director

October 20, 2017 at 02:00 am EDT

Verseon Corporation announced that Dr. Robert W. Karr was elected as a Non-Executive Class II Director of the Company, effective immediately, at the Company's Special Shareholder Meeting held on October 19, 2017.

Latest news about Verseon Corp

Verseon Gains US Patent Protection for Compounds That Could Eliminate Bleeding Risks of Current Anticoagulants	Jan. 24	CI
Verseon Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-30	CI
Verseon Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	19-06-28	CI
Verseon Corporation Auditor Raises 'Going Concern' Doubt	19-06-27	CI
Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs	19-06-04	CI
Verseon Corporation Presents Preclinical Efficacy Data for the First Development Candidate for Clinical Trials in Their Diabetic Eye Disease Program at ARVO 2019	19-04-30	CI
Verseon Corporation announced that it has received $0.1014 million in funding	19-04-23	CI
Verseon Corporation will Change its Ticker to VERS from VSN	19-03-18	CI
Verseon Corporation announced that it expects to receive $0.1014 million in funding	19-03-17	CI
Verseon Corporation Announces First Participants Receive Verseon PRrecision Oral AntiCoagulant in Phase I Trial	19-02-04	CI
Verseon Corporation Announces Resignation of Xavier Rolet as Non-Executive Director	19-01-29	CI
Verseon Corporation Announces Board Changes	18-11-06	CI
Verseon Corporation Unveils Transformative Blockchain Technology for Tokenized Securities	18-09-18	CI
Verseon Commences Phase I Trial for Precision Oral Anticoagulant VE-1902	18-09-13	CI
Verseon Corporation Provides Interim Report Charts Progress of Development Programs as it Submits Phase I Protocol for Precision Anticoagulant	18-08-14	CI
Verseon Corporation Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	18-08-08	CI
Verseon Corporation Submits Phase I Protocol for VE-1902	18-07-18	CI
Verseon Corporation Announces Consolidated Earnings Results for the Year Ended December 31, 2018	18-06-25	CI
Verseon Preparing for Anticoagulant Phase I Trial	18-06-14	CI
Verseon Presents New Preclinical Data on Its Novel Class of Precision Oral Anticoagulants	18-06-07	CI
Verseon Presents New Efficacy Results on Oral Diabetic Macular Edema Drug Candidate at Vision and Ophthalmology Conference	18-05-02	CI
Verseon Corporation Presents Anticancer Agents Targeting Multidrug Resistant Tumors At Cancer Research Conference	18-04-18	CI
Verseon Corporation Presents Second Anticoagulant Candidate for Clinical Trials Presented at AHA 2017	17-11-15	CI
Verseon Corporation Presents Anticancer Agents for Multidrug Resistant Tumors at Bio-Europe 2017	17-11-08	CI
Verseon Corporation Appoints Robert W. Karr as Non-Executive Class II Director	17-10-20	CI

Chart Verseon Corp

Duration

Period

More charts

Company Profile

Verseon Corporation is a pharmaceutical company. The Company's platform models interactions between a protein and a drug molecule with precision sufficient for designing drug candidates. The Company operates through the pharmaceutical research segment. The Company uses its drug discovery technology to develop a portfolio of programs targeting disease areas consisting of anti-coagulation, diabetic macular edema (DMA) and oncology. The Company's platform generates a range of drug-like, synthesizable compounds, which are then computationally tested against a disease-causing protein to identify the binders, the drug candidates that could potentially treat the disease. These computationally designed candidates are synthesized and sent through a series of disease specific in vitro and in vivo tests to identify the candidates for clinical testing in humans.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research